Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cer...
R. Saloner, L. Cornelis, Joshua Downer et al.· bioRxiv· 0 citations
Abstract Background Renal cell carcinoma (RCC) is characterized by a highly immunosuppressive tumor microenvironment enriched in tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), both of which correlate with poor clinical outcomes. TAMs in RCC commonly exhibit an immunosuppressive phenotype, marked by...
Giuliana P. Mognol, E. Wang, William Harris et al.· The Oncologist· 0 citations
Rising sNfL may precede mobility decline, highlighting sNfL as a potential indicator of functional worsening, and lower sNfL was associated with reduced daily ambulatory activity in progressive MS.
G. Joseph, Megan McCune, R. Bove et al.· Annals of Clinical and Trans...· 0 citations
Low dose anti CD19 CAR T cell therapy was safe, penetrated the CSF effectively, reduced intrathecal humoral activity, modulated peripheral immune tone, and appeared to stabilize EDSS scores, which support the continued investigation of CAR T cell therapy in MS.
S. Gupta, M. Seshadri, R. Dandekar et al.· medRxiv· 0 citations
It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
M. Einsiedler, S. Sandgren, S. Schaedelin et al.· JAMA Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
